US5510102A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Plasma and polymer containing surgical hemostatic adhesives
Assignee: University of California
•
Filing: 1995-01-23
•
Granted: 1996-04-23
•
Expires: 2015-01-23
Abstract
Abstract Autologous platelet-rich plasma and a biocompatible polymer containing hemostatic adhesive agents. The agents have strong hemostatic properties when applied to a bleeding wound or vessel.
Inventors
- 👤 Kent C. Cochrum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 15:58
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/39; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61L; A61L24/00; A61L24/04; A61L24/043; A61L2400/00; A61L2400/04; Y; Y10; Y10S; Y10S128/00; Y10S128/22
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
90 words
A hemostatic adhesive agent for triggering clotting process comprising of a platelet-rich plasma concentrate and a physiologically acceptable biocompatible polymer selected from the group-consisting of alginates, poly-L-amino acids, chitosan and chitin wherein the platelet-rich plasma concentrate is 5 to 10 times concentrated normal plasma, said concentrate containing 5 to 10 times higher concentration of fibrinogen and other plasma proteins than the normal plasma; wherein a platelets to plasma concentrate ratio is from 1:2 to 2:1; and wherein a platelet-rich plasma concentrate to polymer ratio is from 99:1 to 80:20; wt/wt.
Claim 2
Dependent Claim
90 words
A hemostatic adhesive agent for triggering clotting process comprising of a platelet-rich plasma concentrate and a physiologically acceptable biocompatible polymer selected from the group-consisting of alginates, poly-L-amino acids, chitosan and chitin wherein the platelet-rich plasma concentrate is 5 to 10 times concentrated normal plasma, said concentrate containing 5 to 10 times higher concentration of fibrinogen and other plasma proteins than the normal plasma; wherein a platelets to plasma concentrate ratio is from 1:2 to 2:1; and wherein a platelet-rich plasma concentrate to polymer ratio is from 99:1 to 80:20; wt/wt.
Claim 3
Dependent Claim
13 words
The agent of claim 1 wherein the plasma is concentrated about 10 times.
Claim 4
Dependent Claim
17 words
The agent of claim 2 wherein the plasma is concentrated from about 7 to about 8 times.
Claim 5
Dependent Claim
11 words
The agent of claim 3 wherein the platelet-rich plasma is autologous.
Claim 6
Dependent Claim
29 words
The agent of claim 1 wherein the polymer is selected from the group consisting of sodium alginate, calcium alginate, strontium alginate, barium alginate, magnesium alginate, and a mixture thereof.
Claim 7
Dependent Claim
20 words
The agent of claim 5 wherein the polymer is sodium alginate added in concentration from about 0.001% to about 20%.
Claim 8
Dependent Claim
18 words
The agent of claim 6 wherein sodium alginate is added in amount from about 0.1% to about 10%.
Claim 9
Dependent Claim
23 words
The agent of claim 4 wherein the polymer is selected from the group consisting of poly-L-lysine, poly-L-histidine, poly-α-D-glutamic acid and a mixture thereof.
Claim 10
Dependent Claim
19 words
The agent of claim 8 wherein the polymer is poly-L-lysine added in concentration from about 0.001% to about 3O%.
Claim 11
Dependent Claim
17 words
The agent of claim 9 wherein poly-L-lysine is added in amount from about 0.1% to about 1%.
Claim 12
Dependent Claim
10 words
The agent of claim 4 wherein the polymer is chitosan.
Claim 13
Dependent Claim
17 words
The agent of claim 11 wherein chitosan is added in amount from about 0.1% to about 10%.
Claim 14
Independent Claim
105 words
A method for attaining hemostasis by triggering clotting process, said method comprising administering, in the presence of a divalent ion, to a site of injury a platelet-rich plasma and a physiologically acceptable biocompatible polymer selected from the group consisting of alginates, poly-L-amino acids, chitosan and chitin, wherein the platelet-rich plasma concentrate is 5 to 10 times concentrated normal plasma, said concentrate containing 5 to 10 times higher concentration of fibrinogen and other plasma proteins than the normal plasma; wherein a platelets to plasma concentrate ratio is from 1:2 to 2:1; and wherein a platelet-rich plasma concentrate to polymer ratio is from 99:1 to 80:20 wt/wt.
Claim 15
Independent Claim
105 words
A method for attaining hemostasis by triggering clotting process, said method comprising administering, in the presence of a divalent ion, to a site of injury a platelet-rich plasma and a physiologically acceptable biocompatible polymer selected from the group consisting of alginates, poly-L-amino acids, chitosan and chitin, wherein the platelet-rich plasma concentrate is 5 to 10 times concentrated normal plasma, said concentrate containing 5 to 10 times higher concentration of fibrinogen and other plasma proteins than the normal plasma; wherein a platelets to plasma concentrate ratio is from 1:2 to 2:1; and wherein a platelet-rich plasma concentrate to polymer ratio is from 99:1 to 80:20 wt/wt.
Claim 16
Dependent Claim
11 words
The method of claim 13 Wherein the platelet-rich plasma is autologous.
Claim 17
Dependent Claim
40 words
The method of claim 13 wherein the polymer is the alginate selected from the group consisting of sodium alginate, calcium alginate, strontium alginate, barium alginate, magnesium alginate, and a mixture thereof added in concentration from about 0.001% to about 20%.
Claim 18
Dependent Claim
35 words
The method of claim 13 wherein the polymer is the poly-L-amino acid selected from the group consisting of poly-L-lysine, poly-L-histidine, poly-α-D-glutamic acid and a mixture thereof added in concentration from about 0.001% to about 30%.
Claim 19
Dependent Claim
11 words
The method of claim 14 wherein the divalent ion is calcium.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-04-23 | 1999-10-23 | 2000-04-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-04-23 | 2003-10-23 | 2004-04-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-04-23 | 2007-10-23 | 2008-04-23 | $7700.00 | Window Closed / Lapsed |